Materias dentro de su búsqueda.
Mostrando 1,801 - 1,820 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.78s Limitar resultados
  1. 1801
    por Scherbakov, A. M., Andreeva, O. E.
    Publicado 2015
    “…It was shown that high doses of apigenin (50 μM) do not display estrogen-like activity and can suppress ER activation by 17β-estradiol. Cultivation of HER2-positive breast cancer SKBR3 cells in the presence of apigenin resulted in a decrease in HER2/neu expression, accompanied by cleavage of an apoptosis substrate PARP. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
  2. 1802
    “…The mean ADC value of HER2-positive gastric cancers was significantly higher than those of HER2-negative tumors (1.211 vs. 0.984 mm(2)/s, P = 0.020). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study
  3. 1803
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis
  4. 1804
    “…In women with T1 or T2 tumors, mastectomy rates were higher in women with Her2 positive tumors than in those with Her2 negative tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her2 positivity and race predict higher mastectomy rates: a SEER database analysis
  5. 1805
    “…Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
  6. 1806
    “…Drug resistance is a major barrier to successful cancer treatment. For patients with HER2-positive breast cancer who initially respond to therapy, the majority develop resistance within one year of treatment. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
  7. 1807
    “…Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
  8. 1808
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Long-term Survival after Resection of HER2+ Infiltrating Ductal Carcinoma Metastasis to the Brainstem
  9. 1809
    “…PURPOSE: We sought to determine whether human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF) expression were independent prognostic factors for gastric cancer (GC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer
  10. 1810
    “…Here we describe 2 cases of diffuse cutaneous metastases from HER2-overexpressing breast cancer occurring despite a dramatic response in liver and bone, respectively, during treatment with anti-HER2 antibodies Trastuzumab and Pertuzumab. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
  11. 1811
    “…BACKGROUND: Targeted anti-HER2 therapy has greatly improved the prognosis for many breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids
  12. 1812
    “…The platform’s performance was first evaluated on cell lines, showing robust operation on RNA quantities corresponding to less than one cell, and then clinically validated with a cohort of 21 breast cancer samples, for the determination of their HER2 expression status, in a blind comparison with an established routine clinical analysis.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis
  13. 1813
    “…BACKGROUND: Many laboratories are currently evaluating the usefulness of the determination of human epidermal growth factor receptor 2 (HER2), p53, and Ki67 proliferation indices using immunohistochemical techniques in cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Coexistence of HER2, Ki67, and p53 in Osteosarcoma: A Strong Prognostic Factor
  14. 1814
    “…Extensive investigation on the underlying molecular mechanisms has revealed a multifaceted role for p62 in HER2-associated mammary tumorigenesis.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis
  15. 1815
    “…Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer is a major clinical problem. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
  16. 1816
    “…NIST standard reference material (SRM) 2373 was developed to improve the measurements of the HER2 gene amplification in DNA samples. SRM 2373 consists of genomic DNA extracted from five breast cancer cell lines with different amounts of amplification of the HER2 gene. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements
  17. 1817
    “…The equivalence of the methodologies was demonstrated by FISH analysis of HER2 amplification in breast cancer cases. The 24‐h postfixation step of the slides used for FISH can be well integrated in the routine diagnostic workflow and allows the remaining PAXgene‐fixed and paraffin‐embedded tissue to be used for further molecular testing.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Protocol for HER2 FISH determination on PAXgene‐fixed and paraffin‐embedded tissue in breast cancer
  18. 1818
    “…The members of the epidermal growth factor receptor (EGFR) kinase family are important players in breast morphogenesis and cancer. EGFR2/HER2 and EGFR expression have a prognostic value in certain subtypes of breast cancer such as HER2-amplified, basal-like and luminal type B. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
  19. 1819
    “…Hormonal receptor profile changes in metastatic lesions favoring human epidermal growth factor receptor 2 (HER2) overexpression may be involved in the pathogenesis of metastasis to the uterus.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The potential role of HER2 upregulation in metastatic breast cancer to the uterus: a case report
  20. 1820
    por Moghaddas, Azadeh, Borhani, Ali
    Publicado 2016
    “…The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
Herramientas de búsqueda: RSS